These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 19210142

  • 1. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.
    van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.
    Curr Med Res Opin; 2009 Jan; 25(1):93-101. PubMed ID: 19210142
    [Abstract] [Full Text] [Related]

  • 2. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group.
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [Abstract] [Full Text] [Related]

  • 3. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.
    Am J Cardiol; 2001 Jan 01; 87(1):44-8. PubMed ID: 11137832
    [Abstract] [Full Text] [Related]

  • 4. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
    van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM, DALI Study Group.
    Diabetes Care; 2003 Apr 01; 26(4):1216-23. PubMed ID: 12663600
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
    Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S.
    Diabetes Technol Ther; 2014 Feb 01; 16(2):63-71. PubMed ID: 24138536
    [Abstract] [Full Text] [Related]

  • 6. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Acta Cardiol; 2006 Jun 01; 61(3):263-9. PubMed ID: 16869445
    [Abstract] [Full Text] [Related]

  • 7. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
    Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J.
    Eur J Pharmacol; 2008 May 31; 586(1-3):259-65. PubMed ID: 18374327
    [Abstract] [Full Text] [Related]

  • 8. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.
    N Engl J Med; 2004 Apr 08; 350(15):1505-15. PubMed ID: 15071125
    [Abstract] [Full Text] [Related]

  • 9. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb 08; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H, Diabetes Atorvastatin Lipid intervention (DALI) Study Group.
    Diabetes Care; 2004 Jun 08; 27(6):1358-64. PubMed ID: 15161788
    [Abstract] [Full Text] [Related]

  • 11. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Am J Cardiol; 2006 Mar 01; 97(5):646-50. PubMed ID: 16490430
    [Abstract] [Full Text] [Related]

  • 12. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.
    Dallinga-Thie GM, van Tol A, Dullaart RP, Diabetes Atorvastatin lipid intervention (DALI) study group.
    Biochim Biophys Acta; 2009 Aug 01; 1791(8):714-8. PubMed ID: 19303940
    [Abstract] [Full Text] [Related]

  • 13. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM.
    J Clin Lipidol; 2015 Aug 01; 9(1):93-102. PubMed ID: 25670366
    [Abstract] [Full Text] [Related]

  • 14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 15. Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis.
    Chang YH, Lin KD, Shin SJ, Lee YJ.
    Nutr Metab Cardiovasc Dis; 2014 Oct 01; 24(10):1067-73. PubMed ID: 24880740
    [Abstract] [Full Text] [Related]

  • 16. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, Simvastatin Atorvastatin HDL Study Group.
    Curr Med Res Opin; 2001 Oct 01; 17(1):43-50. PubMed ID: 11464446
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.
    Expert Opin Ther Targets; 2009 Jul 01; 13(7):743-51. PubMed ID: 19505224
    [Abstract] [Full Text] [Related]

  • 18. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.
    Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A.
    Diabetes Care; 2004 Oct 01; 27(10):2450-7. PubMed ID: 15451915
    [Abstract] [Full Text] [Related]

  • 19. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ, Davidson MH, Caplan RJ, Pears JS.
    Am J Cardiol; 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [Abstract] [Full Text] [Related]

  • 20. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.
    J Clin Lipidol; 2013 Mar 06; 7(4):292-303. PubMed ID: 23890516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.